arrow
C

Cyrille Hulin

chu bordeaux
H指数:45
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

皮下注射isasutuximab(通过自体注射器)联合硼替佐米、来那度胺和地塞米松治疗新诊断的移植不合格多发性骨髓瘤:ISASOCUT研究

2026-10-090
OAAI
MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma

MAIA虚弱亚组分析:在移植不适用的 newly diagnosed myeloma 患者中使用达拉珠单抗联合来那度胺/地塞米松的长-term随访

Leukemia
IF13.4
2026-10-060
OAAI
Longitudinal assessments of MRD in high-risk newly diagnosed transplant-ineligible multiple myeloma in the BENEFIT study (IFM2020-05)

BENEFIT研究(IFM2020-05)中高危初诊非移植候选多发性骨髓瘤的MRD纵向评估

2026-10-050
OAAI
Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis

达拉妥木单抗、来那度胺和地塞米松在移植不适宜的新诊断多发性骨髓瘤中的应用:MAIA最终生存分析

Leukemia
IF13.4
2026-08-240
OA
Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

达拉妥单抗联合硼替佐米、来那度胺和地塞米松在延迟移植的新诊断多发性骨髓瘤中的应用:CEPHEUS研究中的虚弱亚组分析

Leukemia
IF13.4
2026-08-180
OA
Clinical outcomes of newly diagnosed myeloma patients with SLIM criteria : a subgroup analysis of the CASSIOPEIA study

新诊断多发性骨髓瘤患者SLIM标准下的临床结局:CASSIOPEIA研究中的亚组分析

Leukemia
IF13.4
2026-08-130
PRE
Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial

Cyclin D1过表达多发性骨髓瘤的反应特征和长期结局:来自CASSIOPEIA试验的见解

2026-07-030
OAAI
Assessing the benefit of incorporating ananti-CD38 monoclonal antibody into second-or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study

评估将抗CD38单克隆抗体纳入复发/难治性多发性骨髓瘤患者二线或三线系统性治疗中的获益:法国真实世界EMMY研究的结果

2026-02-010
OAAI
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM)

通过大型开放式网络课程(MOOC)为多发性骨髓瘤患者及照护者提供以患者为中心的教育:法国多发性骨髓瘤患者协会(AF3M)和法语骨髓瘤协作组(IFM)关于知识增长的描述性研究

2026-01-010
PRE
35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

35年专注于高剂量疗法和自体干细胞移植的学术研究:法国骨髓瘤研究组(IFM)的经验

2025-10-240
OA
Real-world utilization of carfilzomib (once or twice weekly) initiated in patients after a first relapse between 2017-2022 in France: an analysis from a large-scale Epidemiology of Multiple MYeloma (EmmY) cohort

2017-2022年间法国在首次复发后的多发性骨髓瘤患者中开始使用卡非佐米(每周一次或两次)的实时应用:来自大规模多发性骨髓瘤流行病学(EmmY)队列的分析

2025-08-070
OAAI
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study

抗CD38单克隆抗体在初诊多发性骨髓瘤患者一线治疗中的影响:来自EMMY研究的真实世界结果

2025-07-240
PRE
Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study

基于抗CD38的联合方案在多发性骨髓瘤中的真实世界再治疗:来自Emmy队列研究的结果

2025-05-210
OAAI
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results

达拉妥单抗-硼替佐米-沙利度胺-地塞米松用于新诊断的骨髓瘤:CASSIOPEIA微小残留病结果

Blood
IF23.1
2025-03-260
OA
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort

80岁及以上多发性骨髓瘤患者的真实世界管理:EMMY队列研究结果

2025-02-010
PRE
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Teclesitamab在复发难治性多发性骨髓瘤中的应用:一项来自法国早期准入项目的多中心真实世界研究

2024-11-211
OA
Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again

真实世界中t(11-14)型多发性骨髓瘤使用Venetoclax的多中心数据。是时候再次考虑它了。

BLOOD
IF23.1
2024-11-050
PRE
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

daratumumab联合硼替佐米,来那度胺和地塞米松治疗新诊断的多发性骨髓瘤的PERSEUS研究的简明语言摘要

2024-09-170
OA